Michelle Lynn Hall is a scientist and investor whose career spans small molecules, RNA therapeutics, nanomedicine, gene editing, and gene therapy. Trained as a chemist, she earned her Ph.D. at Columbia University and completed a postdoc at Yale and Novartis. She began her career in small-molecule design at Schrödinger before moving to Moderna, where she focused on mRNA therapeutics, lipid nanoparticles, and protein engineering. She later joined Eli Lilly, where she built and led the Boston Genetic Medicines group as Associate Vice President. Michelle is now a General Partner of Entrée Bio, a venture fund focused on deep-tech-enabled platform biotechnology and next-generation drug discovery.